Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
RC48
Description:
A HER2-targeting antibody-drug conjugate, also known as disitamab vedotin, investigated as a cancer treatment.
Primary topic:
Bladder and Urothelial Cancer Treatments (31%)
Related topics:
Bladder and Urothelial Cancer Treatments (31%),
HER2/EGFR in Cancer Research (23%),
Gastric Cancer Management and Outcomes (18%)
OpenAlex ID:
keywords/rc48
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
2019
·
Gabriel Rinnerthaler
, Simon Peter Gampenrieder
, et al.
·
International Journal of Molecular Sciences
·
243
PDF
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
2022
·
Fan Shi
, Yanli Liu
, et al.
·
Drug Delivery
·
236
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
2021
·
Zhi Peng
, Tianshu Liu
, et al.
·
癌症:英文版
·
230
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
2021
·
Yingying Xu
, Yakun Wang
, et al.
·
Gastric Cancer
·
163
PDF
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
2024
·
Yakun Wang
, Jifang Gong
, et al.
·
EClinicalMedicine
·
96
PDF
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway
2023
·
Xiaohan Wu
, Lingyan Xu
, et al.
·
Cell Death and Disease
·
56
PDF
Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
2023
·
Qing Wei
, Teng Yang
, et al.
·
Clinical Cancer Research
·
52
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
2023
·
Meiting Chen
, Kai Yao
, et al.
·
Cancer Immunology Immunotherapy
·
52
PDF
Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD ‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study
2023
·
Jingwei Xu
, Hongqiao Zhang
, et al.
·
Cancer Medicine
·
36
PDF
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
2023
·
Huizi Lei
, Yun Ling
, et al.
·
Journal of the National Cancer Center
·
36
HER2+ advanced gastric cancer: Current state and opportunities (Review)
2024
·
Hui-Hui Hu
, Sai-Qi Wang
, et al.
·
International Journal of Oncology
·
32
PDF
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
2024
·
Weisong Li
, Kai Zhang
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
29
PDF
The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy
2023
·
Xingliang Tan
, Yanjun Wang
, et al.
·
European Journal of Cancer
·
26
Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
2023
·
Caiyun Nie
, Weifeng Xu
, et al.
·
BMC Cancer
·
25
PDF
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
2024
·
Hongfu Liu
, Dongdong Zhou
, et al.
·
Cell Death and Disease
·
21
PDF
Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
2025
·
Xu Chen
, Ming Huang
, et al.
·
MedComm
·
19
PDF
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
2025
·
Jiatong Xiao
, Jinhui Liu
, et al.
·
Journal for ImmunoTherapy of Cancer
·
18
Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
2022
·
Zhenying Xu
, Jiaman Ma
, et al.
·
Frontiers in Immunology
·
17
PDF
Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study
2024
·
Fei Qu
, Rongrong Lu
, et al.
·
Frontiers in Oncology
·
16
PDF
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China
2024
·
Jinchao Chen
, Mingchao Wang
, et al.
·
Clinical Genitourinary Cancer
·
15
Disitamab vedotin, a novel HER2-directed antibody–drug conjugate in gastric cancer and other solid tumors
2022
·
Yixuan Hu
, Yinxing Zhu
, et al.
·
Drugs of today
·
15
The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
2025
·
Huaixi Ge
, Changxue Liu
, et al.
·
Journal of Translational Medicine
·
14
Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: a comparative analysis of efficacy and safety in muscle-invasive bladder cancer
2025
·
Chuanao Zhang
, Yanhang Yu
, et al.
·
Frontiers in Immunology
·
12
Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report
2024
·
Zhuixing Liu
, Fang Wang
, et al.
·
Frontiers in Immunology
·
12
Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study
2025
·
Xuanjun Guo
, Shuoyu Wang
, et al.
·
npj Precision Oncology
·
11
PDF
Show more works
View as search
Works count:
123
Citation count:
1,714
Year
Topic
Type